Stem Cell Therapies – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2023-2030)

Stem Cell Therapies

• Stem cells are used in the replenishment of blood and immune systems. Apart from their use in the immuno-reconstitution, the stem cells have been reported to contribute in the tissue regeneration and as delivery vehicles in the cancer treatments.
• Stem cells are progenitor cells that are unique in that they are unclassified cells that can modify to become virtually any kind of cell in the body (totipotent).
• Because of the potential that stem cells can replace defective or damaged cells resulting from a variety of disorders and injuries, an increased focus is noticed leading to a range of new regenerative therapies.
• Today, we can extract, artificially grow, and transplant them into the body to treat neurodegenerative and autoimmune disorders.
• Prevailing pipeline candidates for cardiovascular indications are in preclinical development, with ~73% of stem cell pipeline therapies explicitly targeting cardiovascular indications.
• Currently, there is a lack of big pharma investment in the application of stem cell therapy to cardiovascular clinical development, small biotech companies have undertaken most of the R&D efforts in this space.
• Introduction of mesenchymal stem cells therapy is presaged as one of the most promising investigational approaches by the market research analysts.
• The placental stem cells field is projected to grow at the exponential rate; owing to the global mount in the number of placental and cord banks conjugated with growing public awareness.
• The surge in neurodegenerative diseases and massive investments in adult stem cell research are factors that are contributing to the market growth.
• Most studies are in clinical phase trials, among which more percentage of studies are under early phase, phase1, phase 2 compared to phase 3 trails. NLA-101 of Nohla, MGTA-456 of Magenta Therapeutics are under phase 2 stage of development.
• Gamida’s stem cell therapies are in late-stage of development raising expectations on the therapies to be available to patients in the foreseeable future.
• Factors like public awareness affiliated to the therapeutic potential of stem cells; development of latest technologies for stem cell preservation, processing, and storage; increasing number of stem cell-based research and rising number of hematopoietic stem cell transplantations have led to the market growth of stem cell banking.
• However, the high operational costs associated with, and stringent regulatory frameworks are expected to restrain the growth of the market.